Clichy

• A clinical study to assess how safe and effective it is for subjects with hepatocellular carcinoma (HCC) to receive radiation therapy with T … Ended recruitment
  2023-508945-41-00 4 2023-10-11 Hepatocellular Carcinoma
• SIERRA: Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma Ended recruitment
  2022-502012-37-00 5 2023-10-06 Advanced Hepatocellular Carcinoma
• A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis Ended recruitment
  2024-510627-20-00 5 2023-07-28 Non-alcoholic Steatohepatitis (NASH) Cirrhosis
• Phase 1b study investigating the association of NP137 with Atezolizumab-Bevacizumab combination in first line in unresectable hepatocellular … Ended recruitment
  2022-500903-38-00 3 2023-02-09 unresectable hepatocellular carcinoma
• A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection Ended recruitment
  2022-501901-10-00 6 2023-02-06 Chronic Hepatitis D Infection
• A Study to Evaluate Investigational Therapies in Chronic Hepatitis D Virus Infection. Ended recruitment
  2024-512203-40-00 4 2022-11-24 Chronic Hepatitis D Virus (HDV) Infection
• A global study to evaluate transarterial chemoembolization(TACE) in combination with durvalumab, tremelimumab +/-lenvatinib therapy compared … Ended recruitment
  2023-508701-24-00 5 2022-11-21 Locoregional Hepatocellular Carcinoma (HCC)
• TACE-3: A two-arm multi-stage (TAMS) seamless phase II/III randomised trial of nivolumab in combination with TACE/TAE for patients with inte … Ended recruitment
  2024-513882-38-00 10 2022-10-12 Intermediate stage Hepatocellular carcinoma
• SPLEMENGO - Multicenter, randomized, phase III, trial assessing the immunogenicity and safety of three meningococal B vaccine strategies amo … Ended recruitment
  2024-513649-35-00 5 2022-09-15 Asplenia
• Long-term follow-up study to evaluate durability of treatment response in previous bepirovirsen study participants (B-Sure). Ended recruitment
  2023-506867-33-01 4 2022-01-25 Chronic Hepatitis B
• Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial of therapeutic escalation, the POMEROL tri … Ended recruitment
  2023-508242-18-00 6 2021-12-21 Crohn's disease
• A clinical study to assess the efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirr … Ended recruitment
  2023-508248-23-00 5 2021-11-26 Non-alcoholic steatohepatitis (NASH)
• Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors Ended recruitment
  2023-503905-12-00 4 2021-08-20 Liver cancer; Colon cancer; Pancreatic cancer; Bile Duct or Gallbladde
• Long-term safety of apraglutide in short bowel syndrome Ended recruitment
  2023-510389-28-00 5 2021-06-14 short bowel syndrome
• Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing c … Ended recruitment
  2024-511658-28-01 5 2021-04-06 primary sclerosing cholangitis
• Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended recruitment
  2023-506962-30-00 5 2021-03-29 Non-alcoholic steatohepatitis (NASH)
• A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease. Ended recruitment
  2023-508290-81-00 5 2020-12-18 Immunoglobulin G4-related disease (IgG4-RD)
• The USTAP CD trial USTekinumab in fistulising Perianal Crohn’s Disease: The USTAP CD study Ended recruitment
  2023-503380-42-00 6 2020-11-16 patient with moderate to severe Crohn's disease with at least one acti
• Study to evaluate the safety and efficacy of nivolumab combined with ipilimumab as first-line (1L) therapy for participants with advanced HC … Ended recruitment
  2023-508635-31-00 5 2019-12-03 Hepatocellular Carcinoma
• A clinical trial to evaluate the safety and effectiveness of MGL-3196 (resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and … Ended recruitment
  2024-510626-89-00 5 2019-11-18 Non-Alcoholic Steatohepatitis (NASH)
• A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in combination with best supportive … Ended recruitment
  2023-507443-10-00 5 2019-11-04 Patients with somatostatin receptor positive, well-differentiated G2 a
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2023-504718-31-00 10 2019-10-19 Moderately to Severely Active Ulcerative Colitis
• Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1) Ended recruitment
  2023-507405-34-00 5 2019-08-07 First-line patients with advanced biliary tract cancers (BTC)
• A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as pre-operative treatment f … Ended recruitment
  2024-514705-62-00 5 2019-07-08 Recurrent rectal cancer after local excision

Showing 121–144 of 177 trials